The Michael J. Fox Foundation for Parkinson's Research (MJFF) is a New York-based nonprofit founded in 2000. It is the world's largest nonprofit funder of Parkinson's disease research, having raised over $2 billion for Parkinson's programs. MJFF employs a venture philanthropy model, providing non-dilutive funding to early-stage academic and biotech projects to build data packages that attract larger investors.

It also runs major infrastructure programs including the Parkinson's Progression Markers Initiative (PPMI), the world's most deeply characterized Parkinson's cohort, and the LRRK2 Investigative Therapeutics Exchange (LITE). MJFF funds therapeutic development, biomarker research, imaging tracers, and clinical trials. It has supported hundreds of companies and academic programs. Companies funded by MJFF have gone on to raise significant venture capital. MJFF also supports Neumirna Therapeutics (RNA therapies for Parkinson's/epilepsy) through the Michael J. Fox Foundation for Parkinson's Research.